Spermosens AB

🎉 New Year’s Greetings from Spermosens: Reflecting on 2024 and Looking Ahead to 2025 🌟 As 2024 comes to a close, I’d like to take a moment to reflect on what has been a transformative and exciting year for Spermosens. Together, we’ve made strong progress, laying the foundation for a promising 2025. Our unique and patented JUNO-Checked technology continues to advance male fertility diagnostics. This groundbreaking innovation helps address a critical challenge in fertility care: understanding sperm cells' ability to bind to the egg, a key factor in successful fertilization. With over 3 million IVF treatments performed globally each year—but with fewer than 20% resulting in success—there is a clear and growing need for better diagnostics. JUNO-Checked addresses this gap, offering new hope to couples and invaluable support to sperm banks and fertility clinics. 💡💑 ✨ What we achieved in 2024: 🚀 Launched a revised strategy focusing on clinical validation and commercialization through partnerships. ✅ Reached a key milestone with the approval of our clinical study in Malmö, with highly encouraging interim results. 💰 Secured critical financing of approximately SEK 10.7 million, enabling us to continue our clinical study and pursue licensing agreements. 🌍 Engaged in promising discussions with potential partners in the U.S., Japan and Europe, including sperm banks recognizing the value of our technology. 🌟 Looking ahead to 2025: We are well-positioned to build on this momentum. Our focus will remain on: 🔬 Generating strong clinical evidence through our ongoing study, with regular updates expected. 🤝 Strengthening partnerships and finalizing licensing agreements to bring JUNO-Checked to major markets. 💕 Helping millions of couples struggling to conceive by providing innovative solutions that improve fertility care. Finally, I’d like to give my heartful thanks to CFO Ulrik Nilsson for his great contributions as he steps down at the end of December. We’re grateful for his dedication, and we look forward to welcoming Alexander Dahlquist as our new CFO. To everyone who has supported us—our team, business partners and shareholders—thank you. 🙏 Your belief in Spermosens drives us forward. On behalf of the entire team, I wish you a happy and prosperous New Year! 🎆✨ Together, we look forward to a successful 2025! Warm regards, Tore Duvold CEO, Spermosens #Infertility #FertilityCare #ART #MaleFertility #Innovation #Biotechnology #Diagnostics #IVF #JUNOChecked #Spermosens #IVF #Spermbank

5 Reasons to Invest in Spermosens At Spermosens, we are in the process of transforming fertility diagnostics with a focused approach and innovative solutions. Here’s why investing in Spermosens may be a compelling opportunity: 1️⃣ Unique Technology and High Unmet Need Our patented JUNO-Checked system addresses a critical gap in male fertility diagnostics, offering a unique solution to improve donor selection for sperm banks and enhance IVF success rates. 2️⃣ Addressing a Billion-Dollar Market We target the vast fertility care market, valued at over USD 5 billion, focusing on sperm banks and IVF clinics—key players in fertility care worldwide. 3️⃣ Commercialization Through Partnerships Our approach prioritizes licensing agreements and strategic partnerships in major regions, including the US, Europe and Japan, to bring our patented technology to market efficiently. 4️⃣ Ongoing Clinical Study with Value Triggers Our clinical study continues to progress, delivering critical milestones that validate JUNO-Checked’s diagnostic potential, strengthening its appeal to global partners. 5️⃣ Limited Capital Need By focusing on partnerships and maintaining cost-efficiency, we’ve structured our approach to achieve milestones with reduced capital requirements. While Spermosens presents a compelling opportunity, it’s essential to remember that all investments involve risks. We encourage potential investors to consider both the potential and associated risks carefully. Learn more about investing in Spermosens: https://lnkd.in/dVKu_TGj #FertilityDiagnostics #GlobalPartnerships #Innovation #Spermosens #InvestmentOpportunity #spermbank

Spermosens advances male fertility diagnostics targeting global sperm banks At Spermosens, we are making solid progress in our mission to transform male fertility diagnostics. With a clear commercial strategy, we are targeting the billion-dollar sperm bank market through strategic partnerships in key regions, including the US, Europe, Japan and South Korea. Our unique and patented JUNO-Checked system is designed to enhance donor selection and improve IVF success rates, addressing important gaps in male fertility care. In parallel, we are pleased to provide an update on our ongoing clinical study, which continues to show good progress as we work towards validating the diagnostic potential of JUNO-Checked. This progress is a critical step as we search global partnerships and licensing agreements. We are excited about the growing interest in our technology and the opportunity to improve fertility outcomes worldwide. To learn more, check out our latest press releases: https://lnkd.in/d6Nq9cd4 https://lnkd.in/dSCc2i9j #FertilityCare #SpermBank #FertilityDiagnostics #Innovation #GlobalPartnerships #ClinicalStudy #Spermosens

Looking forward to the outcome! Driving progress.

🔍 More for Less 🚀 At Spermosens, we're taking a leaner and more focused approach. By prioritizing our clinical study and business development, we have successfully reduced our spending by more than 50% ✂️. This shift isn't just about cost savings—it's about ensuring every resource we allocate is driving the future of male fertility diagnostics forward. With our second-generation JUNO-Checked technology now in place, we've been able to reduce technical development. This means we're channeling our energy into delivering on clinical goals and establishing partnerships that will take us towards commercialization more efficiently and effectively. 🤝 Our partnership and license-based model not only lowers future capital needs but also shortens our pathway to revenue. By collaborating with established partners, we can make a greater impact—delivering our diagnostic solution to key markets without the heavy burden of building our own commercial organization. Spermosens is committed to advancing fertility care, and this strategic shift ensures we're well-positioned to deliver value. 💬 Join the conversation or learn more at www.spermosens.com. #Spermosens #FertilityDiagnostics #MoreForLess #Efficiency #StrategicFocus #MaleFertility 

Patient recruitment surpasses expectations We’re more than happy to share that Spermosens is making solid progress in our ongoing clinical study at RMC, Malmö! Recruitment is advancing ahead of schedule, supported by close collaboration with RMC and consistent performance from our next-generation JUNO-Checked technology. The advancements strengthen our mission to address an important gap in male fertility diagnostics. 👨⚕️💡 With the strong momentum, we target interim results by year-end. These insights will be crucial in validating JUNO-Checked’s potential to help predict male fertility - adding a valuable tool for specialists and couples alike. 🔬❤️ Beyond the clinical study, we’re advancing on multiple fronts: 🤝We recently signed a Memorandum of Understanding with a Japanese partner to explore commercial opportunities in Japan. 📄We received a Notice of Allowance for our broader US patent, solidifying our IP position as we seek further partnerships in the ART sector. This progress is made possible through the continued support of our shareholders, partners, and dedicated team members. To stay updated on our journey, we invite you to explore our recent press releases: https://lnkd.in/dHhRBXBK Thank you for joining us on this exciting journey toward transforming male fertility diagnostics! 🚀 #spermosens #infertility #IVF #ART #spermbank #RMC

🔬 Steady progress at Spermosens 🔬 We continue to recruit couples for our clinical study at the Reproductive Medicine Center (RMC) in Malmö, which aims to demonstrate the diagnostic relevance of our innovative JUNO-Checked technology. 💡 This week, we signed a Memorandum of Understanding with a Japanese company to explore a commercial partnership 🌏 -  a crucial step in expanding JUNO-Checked into key markets like Japan and advancing male fertility diagnostics globally. More good news! 🎉 This week we also received  a Notice of Allowance for our second and broader US patent covering our JUNO-Checked technology. 🧬 This patent expands our intellectual property portfolio and strengthen our position for future partnerships within the assisted reproductive technology (ART) sector. More updates to come as we continue to progress 🔗 #Fertility #Biotech #MedicalInnovation #IVF #Spermosens #ClinicalStudy #Partnership #USPatent #JUNOChecked #ART #RMC

🔍 Why Our Clinical Study Matters: Diving Into Male Fertility and IVF 🧑⚕️👩🔬 Following the successful recruitment of the first couple in our study, Spermosens is moving forward with enrolling more patients! This important clinical study, in collaboration with the Reproductive Medicine Center (RMC) in Malmö, aims to demonstrate diagnostic value of JUNO-Checked, our unique product for assessing male fertility in Assisted Reproductive Therapy (ART). ⚙️ How It Works: JUNO-Checked measures the binding capacity between the sperm protein IZUMO1 and the egg protein JUNO, a key interaction during fertilization. Using semen samples from IVF procedures, we use the JUNO binding to predict IVF outcomes like fertilization rates, embryo development and pregnancy rates. 🔑 Why It’s Important: For Patients & Society: By improving male fertility diagnostics, we hope to increase IVF success rates, giving families a better chance at conception and potentially reducing healthcare costs. 🌍👶 For Licensing Partners: Clinical validation through this study is key to positioning our unique product in the fertility diagnostics space and make our product attractive for partnerships and licensing. 🤝 For Shareholders: As we continue to generate clinical data, we’re building a foundation to establish commercial partnerships and building value for shareholders. 📈💡 Stay tuned for more updates as we continue this important journey. 🚀 #IVF #ART #FertilityStudy #MaleFertility #ClinicalTrial #MedicalInnovation #Licensing #FertilityDiagnostics #ShareholderValue

🔍 Why Our Clinical Study Matters: Diving Into Male Fertility and IVF 🧑⚕️👩🔬 Following the successful recruitment of the first couple in our study, Spermosens is moving forward with enrolling more patients! This important clinical study, in collaboration with the Reproductive Medicine Center (RMC) in Malmö, aims to demonstrate diagnostic value of JUNO-Checked, our unique product for assessing male fertility in Assisted Reproductive Therapy (ART). ⚙️ How It Works: JUNO-Checked measures the binding capacity between the sperm protein IZUMO1 and the egg protein JUNO, a key interaction during fertilization. Using semen samples from IVF procedures, we use the JUNO binding to predict IVF outcomes like fertilization rates, embryo development and pregnancy rates. 🔑 Why It’s Important: For Patients & Society: By improving male fertility diagnostics, we hope to increase IVF success rates, giving families a better chance at conception and potentially reducing healthcare costs. 🌍👶 For Licensing Partners: Clinical validation through this study is key to positioning our unique product in the fertility diagnostics space and make our product attractive for partnerships and licensing. 🤝 For Shareholders: As we continue to generate clinical data, we’re building a foundation to establish commercial partnerships and building value for shareholders. 📈💡 Stay tuned for more updates as we continue this important journey. 🚀 #IVF #ART #FertilityStudy #MaleFertility #ClinicalTrial #MedicalInnovation #Licensing #FertilityDiagnostics #ShareholderValue

🧪 Spermosens Recruits First Couple for Clinical Study on Male Fertility Diagnostic Product I'm pleased to share that Spermosens has reached an important milestone: Last week we recruited the first couple in our clinical study. This study is being conducted at the Reproductive Medicine Center (RMC) in Malmö and is designed to assess the diagnostic value of our next-generation male fertility diagnostic product, JUNO-Checked. This clinical trial is an essential step for Spermosens, as we aim to provide better tools for evaluating male infertility, which remains underdiagnosed. The goal is to offer fertility specialists a more precise and efficient way to assess sperm quality, ultimately helping personalize treatment and improve IVF outcomes. The results from this study will be crucial in our efforts to establish partnerships and licensing agreements. Thank you for your continued interest in our journey. Tore Duvold, CEO of Spermosens #FertilityDiagnostics #ClinicalTrials #IVF #MaleFertility #Spermosens